Skip to main content

Mycobacterium Abscessus Infection

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
EpetraborolePhase 21 trial
Active Trials
NCT07301320Not Yet Recruiting84Est. Dec 2027
Beyond Air
Beyond AirIsrael - Rehovot
1 program
1
Nitric OxidePhase 21 trial
Active Trials
NCT03208764Completed9Est. Apr 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Oregon TherapeuticsEpetraborole
Beyond AirNitric Oxide

Clinical Trials (2)

Total enrollment: 93 patients across 2 trials

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

Start: Mar 2026Est. completion: Dec 202784 patients
Phase 2Not Yet Recruiting

Inhaled Nitric Oxide for Patients With MABSC

Start: Jul 2017Est. completion: Apr 20199 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.